LEWANDROWSKI; Peter

Patent Applications and Registrations

Patent applications and USPTO patent grants for LEWANDROWSKI; Peter.The latest application filed is for "novel immunotherapy against several tumors including gastrointestinal and gastric cancer".

Company Profile

13.34.40

LEWANDROWSKI; Peter - Tuebingen DE
LEWANDROWSKI; Peter - Tuebingen-Hirschau DE
Lewandrowski; Peter - Tuebingen-Unterjesingen N/A DE
Lewandrowski; Peter - Tubingen-Unterjesingen N/A DE
Lewandrowski; Peter - Tuenbingen-Hirschau N/A DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20220265764 - FRITSCHE; Jens ; et al.	2022-08-25
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 11,298,404 - Fritsche , et al. April 12, 2	2022-04-12
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 11,273,200 - Fritsche , et al. March 15, 2	2022-03-15
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20220040259 - FRITSCHE; Jens ; et al.	2022-02-10
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20220016207 - FRITSCHE; Jens ; et al.	2022-01-20
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20220016209 - FRITSCHE; Jens ; et al.	2022-01-20
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20220008506 - FRITSCHE; Jens ; et al.	2022-01-13
Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210346465 - FRITSCHE; Jens ; et al.	2021-11-11
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210346466 - FRITSCHE; Jens ; et al.	2021-11-11
Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210330743 - FRITSCHE; Jens ; et al.	2021-10-28
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210275634 - FRITSCHE; Jens ; et al.	2021-09-09
Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210268063 - FRITSCHE; Jens ; et al.	2021-09-02
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210260160 - FRITSCHE; Jens ; et al.	2021-08-26
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 11,077,171 - Fritsche , et al. August 3, 2	2021-08-03
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20210162004 - FRITSCHE; Jens ; et al.	2021-06-03
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,933,118 - Fritsche , et al. March 2, 2	2021-03-02
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,905,741 - Fritsche , et al. February 2, 2	2021-02-02
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,898,546 - Fritsche , et al. January 26, 2	2021-01-26
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20200330552 - FRITSCHE; Jens ; et al.	2020-10-22
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20200297801 - FRITSCHE; Jens ; et al.	2020-09-24
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20200155645 - FRITSCHE; Jens ; et al.	2020-05-21
Novel And Powerful Mhc-class Ii Peptides Derived From Survivin App 20200078439 - RAMMENSEE; Hans Georg ; et al.	2020-03-12
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,478,471 - Fritsche , et al. Nov	2019-11-19
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20190321442 - FRITSCHE; Jens ; et al.	2019-10-24
Powerful MHC-class II peptides derived from survivin Grant 10,434,136 - Rammensee , et al. O	2019-10-08
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20190290727 - FRITSCHE; Jens ; et al.	2019-09-26
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,420,816 - Fritsche , et al. Sept	2019-09-24
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,357,540 - Fritsche , et al. July 23, 2	2019-07-23
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers Grant 10,159,725 - Fritsche , et al. Dec	2018-12-25
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 10,064,913 - Weinschenk , et al. September 4, 2	2018-09-04
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 9,993,523 - Fritsche , et al. June 12, 2	2018-06-12
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20180125929 - FRITSCHE; Jens ; et al.	2018-05-10
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 9,895,415 - Fritsche , et al. February 20, 2	2018-02-20
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20180000896 - FRITSCHE; Jens ; et al.	2018-01-04
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20170312336 - FRITSCHE; Jens ; et al.	2017-11-02
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20170304399 - FRITSCHE; Jens ; et al.	2017-10-26
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 9,717,774 - Fritsche , et al. August 1, 2	2017-08-01
Powerful MHC-class II peptides derived from survivin Grant 9,498,512 - Rammensee , et al. November 22, 2	2016-11-22
Formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or class II molecules for vaccine Grant 9,289,478 - Lewandrowski , et al. March 22, 2	2016-03-22
Formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or class II molecules for vaccines Grant 9,283,267 - Lewandrowski , et al. March 15, 2	2016-03-15
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers Grant 9,132,177 - Fritsche , et al. September 15, 2	2015-09-15
Immunotherapy against several tumors including gastrointestinal and gastric cancer Grant 9,101,585 - Fritsche , et al. August 11, 2	2015-08-11
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20150147347 - FRITSCHE; Jens ; et al.	2015-05-28
HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Grant 9,023,804 - Weinschenk , et al. May 5, 2	2015-05-05
HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof Grant 9,023,802 - Rammensee , et al. May 5, 2	2015-05-05
Novel And Powerful Mhc-class Ii Peptides Derived From Survivin App 20140127242 - RAMMENSEE; Hans-Georg ; et al.	2014-05-08
Novel And Powerful Mhc-class Ii Peptides Derived From Survivin App 20140086943 - WEINSCHENK; Toni ; et al.	2014-03-27
Powerful MHC-class II peptides derived from survivin Grant 8,647,629 - Rammensee , et al. February 11, 2	2014-02-11
Hla-binding Peptides Derived From Prostate-associated Antigenic Molecules And Methods Of Use Thereof App 20130336922 - Weinschenk; Toni ; et al.	2013-12-19
Novel And Powerful Mhc-class Ii Peptides Derived From Survivin App 20130323272 - Rammensee; Hans Georg ; et al.	2013-12-05
Composition Of Tumor-associated Peptides And Related Anti-cancer Vaccine For The Treatment Of Gastric Cancer And Other Cancers App 20130115188 - Fritsche; Jens ; et al.	2013-05-09
Novel Immunotherapy Against Several Tumors Including Gastrointestinal And Gastric Cancer App 20130045191 - Weinschenk; Toni ; et al.	2013-02-21
Novel Formulations Of Tumour-associated Peptides Binding To Human Leukocyte Antigen (hla) Class I Or Class Ii Molecules For Vaccines App 20120107337 - LEWANDROWSKI; Peter ; et al.	2012-05-03
Hla-binding Peptides Derived From Prostate-associated Antigenic Molecules And Methods Of Use Thereof App 20120082691 - Rammensee; Hans Georg ; et al.	2012-04-05
Methods for the diagnosis and treatment of cancer based on AVL9 App 20110229505 - FRITSCHE; Jens ; et al.	2011-09-22
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers App 20110229524 - FRITSCHE; Jens ; et al.	2011-09-22
Novel immunotherapy against several tumors including gastrointestinal and gastric cancer App 20110229504 - FRITSCHE; Jens ; et al.	2011-09-22
Composition of tumour-associated peptides and related anti-cancer vaccine Grant 7,994,276 - Singh , et al. August 9, 2	2011-08-09
Novel Formulations Of Tumour-associated Peptides Binding To Human Leukocyte Antigen (hla) Class I Or Class Ii Molecules For Vaccine App 20100158929 - LEWANDROWSKI; Peter ; et al.	2010-06-24
Novel And Powerful Mhc-class Ii Peptides Derived From Survivin App 20100029571 - RAMMENSEE; Hans-Georg ; et al.	2010-02-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.